D Milligan

4.3k total citations · 1 hit paper
62 papers, 3.0k citations indexed

About

D Milligan is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, D Milligan has authored 62 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 21 papers in Genetics and 16 papers in Pathology and Forensic Medicine. Recurrent topics in D Milligan's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Hematopoietic Stem Cell Transplantation (12 papers). D Milligan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Hematopoietic Stem Cell Transplantation (12 papers). D Milligan collaborates with scholars based in United Kingdom, Germany and France. D Milligan's co-authors include Barry W. Hancock, David C. Linch, G. Vaughan Hudson, D.A. Winfield, A. H. Goldstone, D. J. Moir, Annabel McMillan, Rajesh Chopra, J. M. Davies and Rosemary A. Barnes and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

D Milligan

60 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1993 768 citations D Milligan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D Milligan United Kingdom	26	1.4k	1.1k	1.1k	1.0k	479	62	3.0k
Stein Kvaløy Norway	31	1.7k 1.2×	342 0.3×	1.5k 1.3×	634 0.6×	370 0.8×	94	3.2k
Thomas G. Gross United States	37	1.4k 1.0×	974 0.9×	2.1k 1.9×	353 0.3×	1.0k 2.1×	127	4.3k
Auke Beishuizen Netherlands	29	718 0.5×	699 0.6×	503 0.5×	347 0.3×	463 1.0×	110	2.5k
Howard J. Weinstein United States	43	1.4k 1.0×	2.2k 1.9×	1.2k 1.1×	694 0.7×	508 1.1×	122	5.4k
Antonio Salar Spain	28	1.8k 1.3×	292 0.3×	1.2k 1.1×	819 0.8×	519 1.1×	153	3.0k
Simon Crouch United Kingdom	20	1.1k 0.8×	322 0.3×	741 0.7×	656 0.6×	199 0.4×	49	2.0k
Louis Letendre United States	25	290 0.2×	1.1k 1.0×	563 0.5×	490 0.5×	399 0.8×	76	2.1k
Guillermo J. Ruíz‐Argüelles Mexico	30	372 0.3×	2.1k 1.8×	521 0.5×	599 0.6×	411 0.9×	307	3.2k
Gerald S. Gilchrist United States	32	751 0.5×	605 0.5×	478 0.4×	221 0.2×	134 0.3×	87	3.1k
Giovanni Rosti Italy	29	228 0.2×	656 0.6×	804 0.7×	298 0.3×	161 0.3×	127	2.7k

Countries citing papers authored by D Milligan

Since Specialization

Citations

This map shows the geographic impact of D Milligan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D Milligan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D Milligan more than expected).

Fields of papers citing papers by D Milligan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D Milligan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D Milligan. The network helps show where D Milligan may publish in the future.

Co-authorship network of co-authors of D Milligan

This figure shows the co-authorship network connecting the top 25 collaborators of D Milligan. A scholar is included among the top collaborators of D Milligan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D Milligan. D Milligan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adams, Darius J., et al.. (2023). Moya moya vasculopathy and MECP2 duplication syndrome. Child s Nervous System. 40(3). 809–812. 1 indexed citations

Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 31(11). 2416–2425. 21 indexed citations

Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2016). A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia. 31(2). 310–317. 17 indexed citations

Nikolousis, Emmanouil, Stephen Robinson, Sandeep Nagra, et al.. (2013). Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant. Leukemia Research. 37(5). 561–565. 23 indexed citations

Medd, Patrick, Andy Peniket, Timothy J. Littlewood, et al.. (2013). Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. Bone Marrow Transplantation. 48(7). 982–987. 9 indexed citations

Burnett, Alan K., Robert K. Hills, Ann Hunter, et al.. (2011). The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia. 25(7). 1122–1127. 35 indexed citations

Michallet, Mauricette, Mohamed Sobh, D Milligan, et al.. (2010). The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia. 24(10). 1725–1731. 25 indexed citations

Cummins, M, Kate Cwynarski, Sarah Marktel, et al.. (2005). Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplantation. 36(12). 1065–1069. 9 indexed citations

Chakrabarti, Suparno, Husam Osman, K.E. Collingham, Chris Fegan, & D Milligan. (2003). Enterovirus infections following T-cell depleted allogeneic transplants in adults. Bone Marrow Transplantation. 33(4). 425–430. 11 indexed citations

10.

Morris, Emma, Charles Craddock, D Milligan, et al.. (2002). Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).. UCL Discovery (University College London). 2 indexed citations

11.

Hale, G, Stephen Cobbold, Nicolás Novitzky, et al.. (2001). CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy. 3(3). 145–164. 35 indexed citations

12.

Advani, Ranjana H., Giuseppe Visani, D Milligan, et al.. (1999). Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) Plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC). Advances in experimental medicine and biology. 457. 47–56. 33 indexed citations

13.

Lumley, Matthew, et al.. (1999). Quality assurance of CFU‐GM assays: inter‐laboratory variation despite standard reagents. European Journal Of Haematology. 62(1). 32–37. 17 indexed citations

14.

Fegan, CD, et al.. (1998). Circulating CD34+ counts and apheresis planning. Hematological Oncology. 16(2). 69–75. 6 indexed citations

15.

Johnson, S.A., Daniel Catovsky, J. A. Child, et al.. (1998). Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Investigational New Drugs. 16(2). 155–160. 33 indexed citations

16.

McQuaker, I. Grant, A. P. Haynes, Stacy Anderson, et al.. (1997). Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study.. Journal of Clinical Oncology. 15(6). 2288–2295. 34 indexed citations

17.

Richards, Stephen J., et al.. (1994). Persistent Clonal Expansions of CD3⁺TCRγδ⁺and CD3⁺TCRαβ⁺CD4⁻CD8⁻Lymphocytes Associated with Neutropenia. Leukemia & lymphoma. 14(5-6). 429–440. 14 indexed citations

18.

Barker, Helen F., Riaz Jan-Mohamed, M. J. Leyland, & D Milligan. (1990). Mitoxantrone, Etoposide and Prednisolone—a Novel Combination in The Treatment of Relapsed and Refractory Lymphoma. Leukemia & lymphoma. 2(1-2). 81–84. 2 indexed citations

19.

Milligan, D, et al.. (1989). MITOXANTRONE INDUCED CONGESTIVE HEART FAILURE IN PATIENTS PREVIOUSLY TREATED WITH ANTHRACYCLINES. British Journal of Haematology. 71(2). 292–293. 11 indexed citations

20.

Milligan, D, André Stark, & A. G. Bynoe. (1987). Hairy cell leukaemia in two brothers. Clinical & Laboratory Haematology. 9(3). 321–326. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact